Investigator-assessed objective response rates
| Response, % (95% CI) . | Best overall response (n = 40) . | Overall response at primary response assessment (n = 40) . |
|---|---|---|
| Overall response | 95.0 (83.1-99.4) | 87.5 (73.2-95.8) |
| CR | 90.0 (76.3-97.2) | 85.0 (70.2-94.3) |
| PR | 5.0 (0.6-16.9) | 2.5 (0.1-13.2) |
| Stable disease | 0 (0-8.8) | 0 (0-8.8) |
| PD | 0 (0-8.8) | 7.5 (1.6-20.4) |
| Data missing∗, % | 5.0 | 5.0 |
| Response, % (95% CI) . | Best overall response (n = 40) . | Overall response at primary response assessment (n = 40) . |
|---|---|---|
| Overall response | 95.0 (83.1-99.4) | 87.5 (73.2-95.8) |
| CR | 90.0 (76.3-97.2) | 85.0 (70.2-94.3) |
| PR | 5.0 (0.6-16.9) | 2.5 (0.1-13.2) |
| Stable disease | 0 (0-8.8) | 0 (0-8.8) |
| PD | 0 (0-8.8) | 7.5 (1.6-20.4) |
| Data missing∗, % | 5.0 | 5.0 |
CR, complete response; PR, partial response; PD, progressive disease
Two patients discontinued study treatment before having any response assessment performed.